2YR企业会员
| 英文名称 | 中文名称 | CAS |
|---|---|---|
| Ezabenlimab | 埃本利单抗 | 2249882-54-8 |
| Demupitamab | 迪木匹妥单抗 | 2249926-74-5 |
| Finotonlimab | 2350298-85-8 | |
| Emerfetamab | 艾鲁妥单抗 | 2250261-27-7 |
| Cirevetmab | 2473240-98-9 | |
| Varokibart | 2643349-04-4 | |
| LEM-14 | 化合物 T9006 | 1814881-70-3 |
| DT2216 | DT2216 | 2365172-42-3 |
| Izuralimab | 2329669-80-7 | |
| Gresonitamab | 格瑞妥单抗 | 2413817-97-5 |
| CYCLOSPORINE | 环孢菌素 | 79217-60-0 |
| Arecoline hydrobromide | 氢溴酸槟榔碱 | 300-08-3 |
| 3-DeazaneplanocinAhydrochloride | 3-去氮腺嘌呤A | 120964-45-6 |
| 2-formyl-3-hydroxybenzoic acid | 2-甲酰基-3-羟基苯甲酸 | 1243461-12-2 |
| ARV-771 | ARV-771 | 1949837-12-0 |
| Epcoritamab | EPCORITAMAB (艾可瑞妥单抗 ) | 2134641-34-0 |
| Pavurutamab | 2250292-39-6 | |
| Depemokimab | 德莫奇单抗 | 2243274-14-6 |
| Nofazinlimab | 诺法利单抗 | 2377845-98-0 |
| Tuvonralimab | 托沃瑞利单抗 | 2417649-44-4 |
| Dalnicastobart | 2642171-59-1 | |
| Forimtamig | 2649379-96-2 | |
| WEHI-539 | WEHI539 | 1431866-33-9 |
| MI-503 | MI-503 | 1857417-13-0 |
| GSK621 | 6-氯-5-(2'-羟基-3'-甲氧基-[1,1'-联苯]-4-基)-3-(3-甲氧基苯基)-1H-吡咯并[3,2-D]嘧啶-2,4(3H,5H)-二酮 | 1346607-05-3 |
| Serclutamab | SERCLUTAMAB (思诺妥单抗 ) | 2140172-41-2 |
| Cotosudil | 化合物 COTOSUDIL | 1258833-31-6 |
| YB-0158 | YB-0158 | 1144043-83-3 |
| BMS-P5 | BMS-P5 | 1549811-36-0 |
| Pimurutamab | 匹姆瑞妥单抗 | 2251771-76-1 |
| Geptanolimab | 杰洛利单抗 | 2348469-43-0 |
| Recaticimab | 瑞卡西单抗 | 2361290-85-7 |
| Vixtimotamab | 2243775-32-6 | |
| Frexalimab | 氟沙林单抗 | 2515463-86-0 |
| (S)-2-Fluoropropanoicacid | (S)-2-氟丙酸 | 57965-29-4 |
| （Empesertib）BAY1161909 | BAY1161909 | 1443763-60-7 |
| (R)-METHYL 3-(5-BROMOPYRIDIN-2-YL)-2-(BOC-AMINO)PROPANOATE | (R)-3-(5-溴吡啶-2-基)-2-((叔丁氧羰基)氨基)丙酸甲酯 | 1391465-94-3 |
| (S)-3-PHENYLCYCLOHEXANONE | (S)-3-苯基环己酮 | 57344-86-2 |
| Peresolimab | PERESOLIMAB | 2411580-63-5 |
| Etevritamab | 艾替瑞妥单抗 | 2329692-74-0 |
| (4R)-4-[(3S,5R,8R,9S,10S,13R,14S,17R)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid | 异石胆酸 | 1534-35-6 |
| Research Grade Casirivimab | 2415933-42-3 | |
| Anti-CD40LG | 252662-47-8 | |
| GW6471 | GW 6471 | 880635-03-0 |
| 3-BroMoiMidazo[5,1-b]thiazole-7-carboxylic acid | 3-溴咪唑并[5,1-B]噻唑-7-羧酸 | 1352898-75-9 |
| Rogaratinib（BAY1163877） | 罗加替尼 | 1443530-05-9 |
| (R)-GNE-140 | (R)-GNE-140 | 2003234-63-5 |
| CA-4948 | CA-4948 | 1801343-74-7 |
| Itraconazole | 伊曲康唑 | 84625-61-6 |
| Demcizumab | Demcizumab | 1243262-17-0 |
| Spartalizumab | 斯巴达珠单抗 | 1935694-88-4 |
| Datopotamab | DATOPOTAMAB (ANTI-TROP2) | 2267989-53-5 |
| Tarlatamab | 塔拉妥单抗 | 2307488-83-9 |
| Sotigalimab | APX005M | 2305607-45-6 |
| Ubamatamab | 乌巴妥单抗 | 2305629-50-7 |
| Sotrovimab | 索托韦单抗 | 2423014-07-5 |
| Latikafusp | 2552814-07-8 | |
| Glofitamab | 格菲妥单抗 | 2229047-91-8 |
| GMB-475 | GMB-475 | 2490599-18-1 |
| methyl (2S)-3-(5-bromopyridin-2-yl)-2-[(2-methylpropan-2- yl)oxycarbonylamino]-propanoate | METHYL3-(5-BROMOPYRIDIN-2-YL)-2-(TERT-BUTOXYCARBONYL)PROPANOATE | 656801-27-3 |
| Clervonafusp Alfa | 韦洛利单抗 | 2250440-41-4 |
| Penpulimab | 派安普利单抗 | 2350298-92-7 |
| Nivatrotamab | 2278244-14-5 | |
| Lomvastomig | 2648840-52-0 | |
| Research Grade Imdevimab | 依米得韦单抗 | 2415933-40-1 |
| (R)-3-PHENYLCYCLOHEXANONE | (R)-3-苯基环己酮 | 34993-51-6 |
| THAL-SNS-032 | THAL-SNS-032 | 2139287-33-3 |
| Diridavumab | Diridavumab | 1393659-46-5 |
| Ensitrelvir | S-217622 | 1471484-62-4 |
| Lorigerlimab | 洛瑞格利单抗 | 2416595-46-3 |
| Pulocimab | 普络西单抗 | 2428381-49-9 |
| Lipustobart | 2639481-06-2 | |
| Emirodatamab | 2449199-61-3 | |
| Izalontamab | 2559704-24-2 | |
| PF-562271 | N-甲基-N-[3-[[[2-[(2-氧代-2,3-二氢-1H-吲哚-5-基)氨基]-5-三氟甲基嘧啶-4-基]氨基]甲基]吡啶-2-基]甲磺酰胺 | 717907-75-0 |
| CPI-0610 | BET抑制剂 | 1380087-89-7 |
| VH-298 | VH298 | 2097381-85-4 |
| LLY-283 | 化合物 T15767 | 2040291-27-6 |
| ACBI-1 | ACBI1 | 2375564-55-7 |
| Ensitrelvir fumarate | S-217622 | 2757470-18-9 |
| Vulinacimab | 2250342-36-8 | |
| Voxalatamab | 沃昔莱妥单抗 | 2411871-58-2 |
| Iparomlimab | 艾帕洛利单抗 | 2417649-33-1 |
| Imvotamab | 2573121-53-4 | |
| Delpacibart | 2653183-68-5 | |
| Muromonab-Cd3 | 莫罗单抗—CD3 | 140608-64-6 |
| beta-Glucuronidase inhibitor 1 | 1-((6,8-dimethyl-2-oxo-1,2-dihydroquinolin-3-yl)methyl)-3-(4-ethoxyphenyl)-1-(2-hydroxyethyl)thiourea | 484006-66-8 |
| ASTX660 | ASTX660 | 1799328-86-1 |
| Dectrekumab | 德屈库单抗 | 1528523-94-5 |
| Pacanalotamab | 2251756-52-0 | |
| Pimivalimab | 2293951-22-9 | |
| Daxdilimab | 达司迪利单抗 | 2245966-28-1 |
| Obrindatamab | OBRINDATAMAB | 2069959-72-2 |
| Dargistotug | 2649362-29-6 | |
| Research Grade Tebentafusp | 对照抗体 | 1874157-95-5 |
| AP20187 | AP 20187 | 195514-80-8 |
| NVP-2 | 化合物NVP-2 | 1263373-43-8 |
| Dilpacimab | Dilpacimab | 1791420-09-1 |
| Serplulimab | SERPLULIMAB (斯鲁利单抗 ) | 2231029-82-4 |
| VB124 | VB-124 | 2230186-18-0 |
联系方式
